Sixteen patients (40%) had ER-positive and Her2-negative breast cancer, 16 (21%) had Her2-positive disease, of which 5 were also ER-positive, and 13 (17%) had triple-negative breast cancer (TNBC). Here, ESR1 is linked to triple-negative breast carcinoma.